RJA
AMPH icon

Raymond James & Associates’s Amphastar Pharmaceuticals AMPH Stock Holding History

Raymond James & Associates’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.66M Buy
116,677
+1,958
+2% +$85.9K ﹤0.01% 1573
2024
Q2 		$4.59M Buy
114,719
+16,574
+17% +$687K ﹤0.01% 1638
2024
Q1 		$4.31M Buy
98,145
+5,486
+6% +$283K ﹤0.01% 1693
2023
Q4 		$5.73M Buy
92,659
+39,916
+76% +$2.1M ﹤0.01% 1449
2023
Q3 		$2.43M Sell
52,743
-2,425
-4% -$132K ﹤0.01% 1901
2023
Q2 		$3.17M Buy
55,168
+31,607
+134% +$1.4M ﹤0.01% 1783
2023
Q1 		$884K Buy
23,561
+483
+2% +$15.8K ﹤0.01% 2525
2022
Q4 		$647K Sell
23,078
-2,834
-11% -$82.3K ﹤0.01% 2710
2022
Q3 		$728K Buy
25,912
+7,629
+42% +$249K ﹤0.01% 2586
2022
Q2 		$636K Buy
18,283
+1,591
+10% +$56.8K ﹤0.01% 2755
2022
Q1 		$599K Buy
+16,692
New +$473K ﹤0.01% 2958
2021
Q1 		– Sell
-13,666
Closed -$275K – 3994
2020
Q4 		$275K Sell
13,666
-1,481
-10% -$28.8K ﹤0.01% 3174
2020
Q3 		$284K Buy
15,147
+1,470
+11% +$29.6K ﹤0.01% 2990
2020
Q2 		$307K Buy
+13,677
New +$250K ﹤0.01% 2907
2019
Q3 		– Sell
-38,231
Closed -$807K – 3608
2019
Q2 		$807K Buy
38,231
+1,944
+5% +$40.6K ﹤0.01% 2348
2019
Q1 		$741K Sell
36,287
-2,873
-7% -$64.4K ﹤0.01% 2386
2018
Q4 		$779K Sell
39,160
-452
-1% -$8.91K ﹤0.01% 2231
2018
Q3 		$762K Buy
39,612
+4,563
+13% +$81.3K ﹤0.01% 2424
2018
Q2 		$535K Buy
35,049
+1,297
+4% +$22.7K ﹤0.01% 2632
2018
Q1 		$633K Buy
33,752
+7,989
+31% +$150K ﹤0.01% 2421
2017
Q4 		$496K Sell
25,763
-455
-2% -$8.5K ﹤0.01% 2538
2017
Q3 		$469K Buy
+26,218
New +$431K ﹤0.01% 2524

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's AMPH Position: Q3 2024 in Review

Raymond James & Associates increased its Amphastar Pharmaceuticals (AMPH) stake by 1.7% in Q3 2024, buying an estimated $85.9K and bringing the position to 116,677 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

Raymond James & Associates first reported a position in AMPH in Q3 2017 and has held it in 22 quarters since. The position peaked at $5.73M in Q4 2023. 279 funds tracked by Wall St. Rank hold AMPH as of Q3 2024.

  • Raymond James & Associates held 116,677 shares of Amphastar Pharmaceuticals worth $5.66M as of Q3 2024.
  • Raymond James & Associates bought 1,958 Amphastar Pharmaceuticals shares in Q3 2024, an estimated $85.9K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1573 holding.
  • Raymond James & Associates first reported a position in Amphastar Pharmaceuticals in Q3 2017 and has held it in 22 quarters since.
  • Raymond James & Associates's Amphastar Pharmaceuticals position peaked at $5.73M in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.